Literature DB >> 12966788

[Multiple myeloma. Diagnosis and therapy].

H Goldschmidt1, F W Cremer, T M Möhler, A D Ho.   

Abstract

Multiple myeloma is one of the 20 most frequent malignancies in Germany. Initial symptoms are usually non-specific. Assessment of bone marrow and laboratory data as well as imaging techniques are essential for diagnosis and prognostic evaluation. Data from molecular cytogenetics have led to a better understanding of the pathogenesis of multiple myeloma. Cytostatic therapy with alcylating agents and glucocorticoids prolongs the survival. High-dose therapy followed by transplantation of autologous hematopoietic stem cells improves prognosis for patients up to the age of 70. Currently, modifications of allogeneic hematopoietic stem cell transplantation, anti-angiogeneic and immunomodulatory drugs as well as proteasome inhibitors are evaluated in clinical trials. Supportive care has derived benefit from the introduction of new bisphosphonates.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12966788     DOI: 10.1007/s00108-003-0920-x

Source DB:  PubMed          Journal:  Internist (Berl)        ISSN: 0020-9554            Impact factor:   0.743


  14 in total

Review 1.  Multiple myeloma and renal failure.

Authors:  H Goldschmidt; H Lannert; J Bommer; A D Ho
Journal:  Nephrol Dial Transplant       Date:  2000-03       Impact factor: 5.992

2.  Total therapy with tandem transplants for newly diagnosed multiple myeloma.

Authors:  B Barlogie; S Jagannath; K R Desikan; S Mattox; D Vesole; D Siegel; G Tricot; N Munshi; A Fassas; S Singhal; J Mehta; E Anaissie; D Dhodapkar; S Naucke; J Cromer; J Sawyer; J Epstein; D Spoon; D Ayers; B Cheson; J Crowley
Journal:  Blood       Date:  1999-01-01       Impact factor: 22.113

Review 3.  Staging and kinetics of multiple myeloma.

Authors:  B G Durie
Journal:  Semin Oncol       Date:  1986-09       Impact factor: 4.929

4.  Smoldering multiple myeloma.

Authors:  R A Kyle; P R Greipp
Journal:  N Engl J Med       Date:  1980-06-12       Impact factor: 91.245

5.  Interferon in multiple myeloma--summary of treatment results and clinical implications.

Authors:  H Ludwig; E Fritz
Journal:  Acta Oncol       Date:  2000       Impact factor: 4.089

Review 6.  Multiple myeloma: an update on biology and treatment.

Authors:  H Ludwig; J Meran; N Zojer
Journal:  Ann Oncol       Date:  1999       Impact factor: 32.976

7.  Chemotherapy for multiple myeloma.

Authors:  R Alexanian; R Dreicer
Journal:  Cancer       Date:  1984-02-01       Impact factor: 6.860

Review 8.  Management of disease-related anemia in patients with multiple myeloma or chronic lymphocytic leukemia: epoetin treatment recommendations.

Authors:  Heinz Ludwig; Kanti Rai; Joan Blade; Franco Dammacco; Laurent Degos; Loretta Itri; Robert Kyle; Vicenzo Liso; Timothy James Littlewood; Franco Mandelli; Giovanna Meloni; Stefano Molica; Anders Osterborg; Gerassimos A Pangalis; Jesus San Miguel; Barbara Schmitt; Dimitrios Voliotis
Journal:  Hematol J       Date:  2002

9.  A clinical staging system for multiple myeloma. Correlation of measured myeloma cell mass with presenting clinical features, response to treatment, and survival.

Authors:  B G Durie; S E Salmon
Journal:  Cancer       Date:  1975-09       Impact factor: 6.860

10.  Clinical staging in multiple myeloma.

Authors:  R K Woodruff; J Wadsworth; J S Malpas; J S Tobias
Journal:  Br J Haematol       Date:  1979-06       Impact factor: 6.998

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.